BNTX BioNTech SE
Company Analysis
Latest News
BioNTech Adds Trodelvy to Pumitamig’s Phase 3 First-Line TNBC Trial
BioNTech SE and Gilead Sciences Inc. announced a clinical trial collaboration and supply agreement to evaluate pumitamig, an investigational bispecific...
🔴 BioNTech is trading 4.3% down today after BNT113 failed to meet a primary endpoint
BioNTech is trading 4.3% down at $91.68 after its BNT113 cancer immunotherapy trial failed to meet its first primary endpoint. - Announced October 13, 2026,...
🔴 BioNTech is trading 6.6% down in pre-market — no clear overnight catalyst identified
BioNTech is trading at $89.50, down 6.62%; sources reviewed surfaced no clear overnight catalyst. - The latest BioNTech headlines found were dated October 9,...
🟢 BioNTech is trading 4.3% up with no clear company-specific catalyst
BioNTech is trading 4.23% higher at $95.95, with no clear company-specific announcement explaining the gain. - Latest reported company news includes plans to...
BioNTech Founders to Step Down and Launch New mRNA-Focused Company, 'Arife'
BioNTech's co-founders, Ugur Sahin and Ozlem Tureci, announced plans to launch a new pharmaceutical company named Arife and will be stepping down from their...
🟢 BioNTech rises 4.1% — Biotech Sector Rallies on Major AI Collaboration Deal and Positive Clinical News
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is trading higher, driven by a...
BioNTech maintains UBS Buy rating, following 92% lung cancer response rate
UBS reiterated its Buy rating for BioNTech. Analysts maintained a $135 price target following the 2026 World Conference on Lung Cancer (WCLC). A combination...
BioNTech's Lung Cancer Drug Nearly Doubles Survival — But Can One Trial Justify a Comeback Story?
Shares of BioNTech surged 6% to $102.55 on September 14, defying a weak market session with Nasdaq futures down nearly 1.5%, after the German biotech reported...
🟢 BioNTech is trading 6% up in pre-market after Phase 3 gotistobart trial showed survival benefit
BioNTech is trading 6.02% up now at $102.55 in pre-market after announcing positive Phase 3 results for gotistobart on September 14, 2026. - Reuters reported...
🔴 BioNTech is trading 4.7% down in after-hours trading amid above-forecast producer inflation and rate uncertainty
BioNTech is trading 4.73% down at $91.84 after broad market weakness; no new company-specific announcement or earnings release clearly explains the after-hours...
🔴 BioNTech is trading 4.1% down today after BMO Capital downgraded shares and cut target
BioNTech is trading 4.1% down at $99.55 after BMO Capital downgraded shares from Outperform to Market Perform and cut its price target from $128 to $105,...
BioNTech Halts Colorectal Cancer Vaccine Trial, Cites Survival Imbalance
BioNTech and partner Genentech terminated a Phase 2 trial for the mRNA-based cancer vaccine autogene cevumeran. The study focused on patients with high-risk...
🔴 BioNTech is trading 9.36% down today despite broader market gains
BioNTech is trading 9.36% down at $100.97, sharply underperforming the broader market, with no clear company-specific catalyst identified. - The FDA approved...
🔴 BioNTech is trading 4.5% down today as Nasdaq Composite falls 0.60%
BioNTech is trading down 4.5% at $111.33 amid a broader risk-off tone, with the Nasdaq Composite down 0.60%. - No new company-specific announcement explaining...
🟢 BioNTech is trading 5% up today on positive cancer-vaccine results from Moderna and Merck
BioNTech is trading 4.85% up now at $116.27, extending the strong August 19, 2026 rally; the move appears driven primarily by investor read-through from...
BioNTech to Reveal Lung Cancer Data, Highlighting Phase 3 Survival Results
BioNTech SE will present new clinical data from its lung cancer development program at the IASLC 2026 World Conference on Lung Cancer. The presentations...
🔴 BioNTech falls 4.9% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
🟢 BioNTech is trading 18% up today after positive melanoma-vaccine results from Moderna and Merck
BioNTech is trading 18% up now at $109.47 after positive Phase 3 melanoma-vaccine results from Moderna and Merck lifted mRNA and biotech sentiment. - Sector...
BioNTech and Pfizer Sued Over mRNA Patents, Risking Vaccine Injunctions
Arbutus and licensee Genevant Sciences filed patent infringement claims against BioNTech and Pfizer at the Unified Patent Court in The Hague. The lawsuit...
🟢 BioNTech is trading 14.29% up in pre-market with no clear company-specific catalyst identified
BioNTech is trading 14.29% up at $106.00 with no clear company-specific catalyst identified for August 19, 2026. - Its latest major event was the August 4...